open pharma
See the following -
Bristol-Myers Squibb Launches Universal Patient Language (UPL), an Open-Source Resource for Improving Patient Communications
The UPL seeks to improve how complex topics are communicated to patients; Company launches UPL.org to make principles and tools widely available to others. Bristol-Myers Squibb today announced its commitment to moving toward a new way of communicating with patients and caregivers: the Universal Patient Language (UPL). The UPL addresses widely voiced concerns among consumers and health care advocates that communications about medicines are not designed for an optimal patient experience...
- Login to post comments
Can Open Science Help Patients And Save Pharma?
Open science research and development hybrid development model can protect pharma company profits while reducing costs of medicines for consumers Read More »
- Login to post comments
Clinovo officially launches a Users and Developers Community for ClinCapture
Clinovo releases its open-source community for users of ClinCapture® and developers around the world to collaborate on the enhancement of its open-source Electronic Data Capture (EDC) system. Read More »
- Login to post comments
Clinovo Pledges $40+ Million in eClinical Technologies and Services to the ACRES Consortium
Clinovo, a leading provider of Cloud-based eClinical software, announces a $40 Million pledge in support of the Alliance for Clinical Research Excellence and Safety (ACRES) global collaborative model, an Alliance that aims to transform the clinical research enterprise through the construction of a global system for clinical research to accelerate medicines development, while enhancing quality, safety and long-term industry sustainability. Clinovo joins ACRES’ strategic allies group, including those the ACRES Tech Consortium which work towards gathering innovative eClinical systems together in a $100+ Million pledge to bring treatments worldwide.
- Login to post comments
Clinovo Speaks On Standards Implementation Strategies For Medical Devices At CDISC Interchange Europe 2014
President & CEO of Clinovo, Ale Gicqueau, was selected to present at the CDISC Interchange Europe 2014. The internationally renowned conference held in Paris, France on the 7-11th April 2014, is the premier venue for clinical trial experts dedicated to implementing and spreading the use of FDA-recommended CDISC standards.
- Login to post comments
Controlled Substances Compliance Expert Community Established
The Pistoia Alliance Controlled Substances Compliance Services (CSCS) project has made it significantly easier for life science companies to comply with controlled substance legislation by establishing an expert community to interpret the often-ambiguous rules. Read More »
- Login to post comments
Deloitte Report: Open R&D Models Increase Chances for Late-Stage Success
Today, as thousands of drug makers interact at the 2015 BIO International Convention, Deloitte is releasing a report suggesting that biopharmaceutical companies could have greater success if they collaborate with other organizations – even competitors – as part of an open innovation approach to research and development. The report – "Executing an Open Innovation Model: Cooperation is Key to Competition for Biopharmaceutical Companies" – shows that drugs sourced via open innovation are three times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach.
- Login to post comments
EDC Scandinavia Uses OpenClinica for BYOD ePro
In a recent study involving several hundreds patients, we decided to offer patients the ability to collect their diary data using their own smart phones instead of the traditional paper diary. The patients who decided to participate in the study downloaded the app to their smart phone or could use their desktop to access the application.
- Login to post comments
eTRIKS 'open source' EU project for sharing vital disease information
Developing a software system that enables pharmaceutical companies, governments, academia and hospitals to share information to advance our understanding of diseases is the focus of a major European Union funded project, which is led by researchers from Imperial College London. Read More »
- Login to post comments
Funds Crunch Hits India's Drug Development Project
Lack of funds is threatening the smooth progress of India’s unique Open Source Drug Discovery (OSDD) project, a first of its kind attempt to develop drugs for neglected diseases, when it is entering a crucial phase of research. Prime Minister Manmohan Singh had in February announced that OSDD, the pet project of the Council of Scientific and Industrial Research (CSIR), had identified a lead (potential drug candidate) for tuberculosis (TB).
- Login to post comments
How Secrecy in Medical Research Harms our Health
Medical research data remain shrouded in secrecy. As a result the data is distorted and misrepresented by pharmaceutical companies launching new medicines to exaggerate their efficacy, minimize their harmful side effects, and conceal the fact that these products are often no more effective than those already on the market. Clinical trials are unnecessarily repeated and overall, health-care and patients suffer. Read More »
- Login to post comments
International Team of Scientists Open Sources Search for Malaria Cure
The Open Source Malaria (OSM) project operates along very similar lines to traditional medicinal chemistry projects in that the team is looking for an antimalarial drug candidate suitable for Phase 1 clinical trials. However, the day to day running of the project works quite differently and is probably most clearly defined by the team’s commitment to The Six Laws of Open Science... Read More »
- Login to post comments
Merck To Bristol-Myers Face Threats On India Patents (Correct)
Pharmaceutical companies from Merck & Co. (MRK:US) to Bristol-Myers Squibb Co. (BMY:US) face fresh threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs for local makers to copy. The panel is looking beyond the cancer treatments it studied last year to areas such as HIV and diabetes, according to two people with knowledge of the matter, who asked not to be identified because the discussions are private.
- Login to post comments
Novaseek Research Wins Pistoia Alliance President's Startup Challenge 2015
Novaseek Research today announced that it is a winner of the inaugural 2015 Pistoia Alliance President's Startup Challenge. The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. The Startup Challenge 2015 panel of expert judges, drawn from the Pistoia Alliance's membership, evaluated more than 30 start-up companies from around the world who are developing new ideas to lower the barriers to innovation in life sciences R&D.
- Login to post comments
Open Source Drug Discovery Test A Success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer...One-third of the labs reported their results in a paper published today in PLOS Pathogens, "Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond." The results have ignited more a dozen drug-development projects for a variety of diseases. "The trial was successful not only in identifying compounds to pursue for anti-malarials, but it also identified compounds to treat other parasites and cancer," said lead author Wesley Van Voorhis.
- Login to post comments